Navigation Links
MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
Date:1/7/2008

- Expands Staff to Continue Record of Investment Success -

GAITHERSBURG, Md., Jan. 7 /PRNewswire/ -- MedImmune, the operationally independent worldwide biologics unit of AstraZeneca plc (LSE: AZN.L, NYSE: AZN), today announced that its highly successful venture capital fund, MedImmune Ventures, will broaden its focus to include areas of strategic interest to both organizations by adding the therapeutic areas of cardiovascular and metabolic disease, pain and central nervous system disorders and gastrointestinal disease. Traditionally, MedImmune Ventures has focused its efforts on the areas of infectious disease, oncology and inflammatory disease. Since its inception in 2002, MedImmune Ventures has invested in 22 companies.

"We look forward to making meaningful investments in these additional therapeutic areas," said Edward T. Mathers, executive vice president, corporate development and venture, MedImmune. "Now that we are more fully aligned with AstraZeneca's core areas of interest, we are able to help both MedImmune and AstraZeneca to stay at the forefront of novel science with a direct window to the most innovative start-ups in the biotechnology industry."

Mr. Mathers and MedImmune President & CEO David M. Mott currently lead MedImmune Ventures. To accommodate the broader disease area focus, MedImmune Ventures has added Maggie Flanagan LeFlore, Ph.D. and Eva M. Jack as managing directors to its team of experts that oversee the assessment of all new investment opportunities. Previously, Dr. LeFlore was on assignment from AstraZeneca to the healthcare and life science venture investment team at Advent International, and Ms. Jack was director, business development at MedImmune. Also, Joseph L. Amprey, M.D., Ph.D. was promoted to managing director of MedImmune Ventures following the June 2007 retirement of its president, Wayne T. Hockmeyer, Ph.D. Franklin H. Top, M.D., who has been with MedImmune since 1988 and is the company's former m
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. MedImmune Announces Seven Key Promotions and New Hires
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
10. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
11. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Lionbridge (Nasdaq: LIOX ) today announced ... master services agreement with a multi-billion dollar ... serve patients in approximately 100 countries. With ... provider for translation of the company,s online ... resources, legal, and corporate communications information. Lionbridge ...
(Date:12/14/2009)... Dec. 14 Decision Resources, one of ... pharmaceutical and healthcare issues, finds that, owing to ... fibrillation drug market will increase more than sevenfold ... in 2018 in the United States, France, Germany, ... The new Pharmacor report entitled Atrial Fibrillation ...
(Date:12/14/2009)... , - Results From ... Rheumatoid Arthritis in Seven Major Industrialized Countries , , ... arthritis say their disease, impacts ... Women living with rheumatoid arthritis find shopping for gifts, ... wrapping presents most, difficult to ...
(Date:12/11/2009)... Corporation (Nasdaq: DNDN ) announced today that ... have exercised in full their option to purchase ... the public offering price of $24.75 per share. ... size of the offering to an aggregate of ... to receive net proceeds from the offering of ...
Breaking Biology Technology:Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 2Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 3The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
... Jan. 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX) ... of AppTec Laboratory,Services, Inc., a US-based service ... AppTec offers testing, contract research and,development, and ... fully integrated platform., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ...
... PALO ALTO, Calif., Jan. 31 CV Therapeutics,Inc. (Nasdaq: ... an Investor Science,Day for the financial community in New ... a.m. EST., The event will be webcast live ... http://www.cvt.com ., About CV Therapeutics, CV Therapeutics, ...
... Discuss Plans for Company in 2008 and Beyond ... Emisphere,Technologies, Inc. (Nasdaq: EMIS ), announced today ... 7, at 10:00 AM EST. President and,Chief Executive ... business strategy. Emisphere is a biopharmaceutical company that,focuses ...
Other Biology Technology:WuXi PharmaTech Completes Acquisition of AppTec 2CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008 2Emisphere to Host Business Strategy Conference Call on February 7 2Emisphere to Host Business Strategy Conference Call on February 7 3
(Date:12/15/2009)... Springer has just signed an agreement with the British ... an affiliation with the journal Biogerontology for ... will appoint one member of the Biogerontology ... issue annually. Springer will sponsor the society and ... Biogerontology on www.springerlink.com . , Biogerontology ...
(Date:12/15/2009)... ancient American horses may have been grazing the ... than previously thought. After plucking ancient DNA from ... researchers used cutting-edge techniques to uncover "genetic fossils" ... to between 7,600 and 10,500 calendar years. This ... of these now-extinct mammals endured longer in the ...
(Date:12/15/2009)... consumers can look forward to ultra-low powered or ... and mobile phones. This is made possible with ... are critical elements for power optimisation and higher ... Analog IC design is the key enabling capability ... the nation in advanced analog and mixed signal ...
Breaking Biology News(10 mins):Late-surviving megafauna exposed by ancient DNA in frozen soil 2Late-surviving megafauna exposed by ancient DNA in frozen soil 3Late-surviving megafauna exposed by ancient DNA in frozen soil 4NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3Prince William Health System Completes Merger With Novant Health to Expand Quality Health Care in Northern Virginia 50528 1Prince William Health System Completes Merger With Novant Health to Expand Quality Health Care in Northern Virginia 50528 2Prince William Health System Completes Merger With Novant Health to Expand Quality Health Care in Northern Virginia 50528 3Infants Should Be Screened for Hip Trouble 50526 1Infants Should Be Screened for Hip Trouble 50526 2Infants Should Be Screened for Hip Trouble 50526 3Christian Childrens Fund Name Change to ChildFund International Official 50524 1Christian Childrens Fund Name Change to ChildFund International Official 50524 2
... retroviral resistance gene, called FEZ1, that can mediate a potent ... cell culture. The researchers found that the high level of ... a significant block to retroviral infection ?retroviruses were able to ... were excluded from entering the host cell nucleus. , "We ...
... much more canny predators than previously thought, ecologists have ... British Ecological Society's Journal of Animal Ecology, basking sharks ... at dawn and surfacing at dusk in order to ... As well as shedding new light on basking behaviour, ...
... the abnormal repetition of a genetic sequence can have ... that govern balance and motor coordination. The studies bolster ... by having extra copies of a normal protein, not ... with the rare neurodegenerative disorder spinocerebellar ataxia type 1 ...
Other Biology News:Plankton can run, but can't hide from basking sharks 2Pinpointing the cause of a neurodegenerative disorder 2Pinpointing the cause of a neurodegenerative disorder 3
... the standard water based mounting medium for ... permanent preservation of peroxidase and alkaline phosphatase ... use and exhibits excellent optical characteristics. Crystal ... medium that permits the long-term storage of ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
Request Info...
US Pharmacopoeia Purified-Water/Water-for-Injection Quality Water...
Biology Products: